SCHEMBL3973430

SCHEMBL3973430

CN(C)C=CC(=O)c1ccc(C(=O)NCCc2ccccc2)s1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 1/20 0.58
HDAC4 P56524 1/20 0.58
HDAC1 Q13547 1/20 0.58
HDAC6 Q9UBN7 1/20 0.58
NPC1 O15118 6/20 0.53
RAB9A P51151 6/20 0.53
SMN1; SMN2 Q16637 4/20 0.53
USP2 O75604 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
ALDH1A1 P00352 6/20 0.50
KDM4E B2RXH2 2/20 0.50
KMT2A Q03164 2/20 0.50
GAA P10253 2/20 0.50
MAPT P10636 3/20 0.49
AKT3 Q9Y243 1/20 0.48
ACKR3 P25106 4/20 0.46
CLK1 P49759 1/20 0.46
LMNA P02545 2/20 0.46
MEN1 O00255 1/20 0.46
TDP1 Q9NUW8 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3973421 1.00 HDAC3 (0.58) HDAC3HDAC4HDAC1HDAC6NPC1
SCHEMBL3978597 0.89 HDAC3 (0.55) HDAC3HDAC4HDAC1HDAC6NPC1
SCHEMBL3971128 0.89 HDAC3 (0.55) HDAC3HDAC4HDAC1HDAC6NPC1
SCHEMBL13992633 0.88 RAB9A (0.64) HDAC3HDAC4HDAC1HDAC6NPC1
SCHEMBL14100177 0.84 RAB9A (0.50) RAB9AALDH1A1MAPTCLK1LMNA
SCHEMBL3977024 0.82 MAPK1 (0.62) NPC1RAB9ASMN1; SMN2USP2ALDH1A1
SCHEMBL3977017 0.82 MAPK1 (0.62) NPC1RAB9ASMN1; SMN2USP2ALDH1A1
SCHEMBL3975181 0.80 HDAC6 (0.68) HDAC3HDAC4HDAC1HDAC6NPC1
SCHEMBL6455155 0.78 HDAC3 (0.65) HDAC3HDAC4HDAC1HDAC6NPC1
SCHEMBL13992638 0.77 AKT3 (0.53) NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1907385-A4 COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2009-05-06 EP disclosed
US-20080194561-A1 carboxyamide thiophenes and medicaments containing the same as well as processes for the preparation and use of such compounds, compositions and medicaments, particularly in diseases associated with inappropriate Aurora activity. SMITHKLINE BEECHAM CORPORATION 2008-08-14 US disclosed
EP-1907385-A2 COMPOUNDS SmithKline Beecham Corporation (US) 2008-04-09 EP disclosed
WO-2007018941-A2 PYRIMIDYL-THIOPHENE DERIVATIVES SMITHKLINE BEECHAM CORPORATION (US) 2007-02-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194561-A1 carboxyamide thiophenes and medicaments containing the same as well as processes for the preparation and use of such compounds, compositions and medicaments, particularly in diseases associated with inappropriate Aurora activity. AURKA, AURKC, AURKB HDAC3 1847/4885HDAC4 1732/4885HDAC1 1504/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.